- Report
- May 2025
- 73 Pages
Global
From €3500EUR$4,108USD£3,104GBP
- Report
- May 2025
- 81 Pages
Global
From €3500EUR$4,108USD£3,104GBP
- Report
- October 2025
- 89 Pages
Qatar
From €4107EUR$4,500USD£3,519GBP
- Report
- July 2025
- 90 Pages
Japan
From €5066EUR$5,550USD£4,341GBP
- Report
- June 2025
- 97 Pages
Asia Pacific
From €3605EUR$3,950USD£3,089GBP
- Report
- June 2025
- 100 Pages
Europe
From €3605EUR$3,950USD£3,089GBP
- Report
- June 2025
- 89 Pages
North America
From €3149EUR$3,450USD£2,698GBP
- Report
- June 2025
- 109 Pages
Global
From €3149EUR$3,450USD£2,698GBP
- Report
- June 2025
- 81 Pages
From €3149EUR$3,450USD£2,698GBP
- Report
- June 2025
- 198 Pages
Global
From €4518EUR$4,950USD£3,871GBP
- Report
- June 2025
- 81 Pages
Middle East, Africa
From €3149EUR$3,450USD£2,698GBP
- Report
- March 2025
- 260 Pages
Middle East
From €2647EUR$2,900USD£2,268GBP
- Report
- March 2025
- 260 Pages
Africa
From €2647EUR$2,900USD£2,268GBP
- Report
- March 2025
- 210 Pages
Latin America
From €2647EUR$2,900USD£2,268GBP
- Report
- March 2025
- 840 Pages
Asia Pacific
From €2647EUR$2,900USD£2,268GBP
- Report
- March 2025
- 980 Pages
Europe
From €2647EUR$2,900USD£2,268GBP
- Report
- March 2025
- 1400 Pages
Global
From €4472EUR$4,900USD£3,832GBP
- Report
- March 2025
- 50 Pages
Kenya
From €548EUR$600USD£469GBP
- Report
- March 2025
- 50 Pages
Nigeria
From €548EUR$600USD£469GBP
- Report
- March 2025
- 50 Pages
Egypt
From €548EUR$600USD£469GBP

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more